Targets › HCAR2
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. (UniProt, Q8TDS4)
Open in Phaseline: the race on HCAR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Indiana University | Extended Release Niacin HCAR2 agonist | HCAR2 | Phase 1 | Alzheimer Disease | Dec 2026 |
Alzheimer Disease (1)
mixed (1)
Indiana University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.